Microbot Medical Company Insiders
| MBOT Stock | USD 2.69 -0.04 -1.47% |
Slightly above 65% of Microbot Medical's corporate insiders are selling. The analysis of insiders' sentiment of trading Microbot Medical stock suggests that many insiders are alarmed at this time. Microbot Medical employs about 20 people. The company is managed by 13 executives with a total tenure of roughly 20 years, averaging almost 1.0 years of service per executive, having 1.54 employees per reported executive.
| Harel Gadot Chairman Chairman of the Board and Presidentident, CEO |
Insider Sentiment
Mostly Selling
Selling | Buying |
Latest Trades
| 2020-10-19 | Yoseph Bornstein | Disposed 4881 @ 7.94 | View | ||
| 2020-10-05 | Yoseph Bornstein | Disposed 20000 @ 7.74 | View | ||
| 2020-08-17 | Yoseph Bornstein | Disposed 15119 @ 10.19 | View | ||
| 2019-01-16 | Alliance Investment Management | Acquired 102309 @ 3.7 | View | ||
| 2019-01-14 | Alliance Investment Management | Acquired 1773 @ 6.44 | View | ||
| 2019-01-09 | Alliance Investment Management | Acquired 14280 @ 2.19 | View | ||
| 2018-11-26 | Alliance Investment Management | Acquired 37986 @ 1.95 | View | ||
| 2018-11-21 | Alliance Investment Management | Acquired 24873 @ 2.21 | View | ||
| 2018-11-19 | Alliance Investment Management | Acquired 2400 @ 3 | View | ||
| 2018-01-09 | Yoseph Bornstein | Disposed 35000 @ 1.06 | View | ||
| 2018-01-02 | Yoseph Bornstein | Disposed 42132 @ 1.01 | View | ||
| 2017-12-27 | Yoseph Bornstein | Disposed 14257 @ 1.02 | View | ||
| 2017-12-19 | Yoseph Bornstein | Disposed 32067 @ 1.03 | View | ||
| 2017-12-12 | Yoseph Bornstein | Disposed 44159 @ 1.04 | View | ||
| 2017-12-06 | Yoseph Bornstein | Disposed 15375 @ 1.05 | View | ||
| 2017-12-04 | Yoav Zvi Waizer | Acquired 10000 @ 1.1 | View | ||
| 2017-11-28 | Yoseph Bornstein | Disposed 45000 @ 1.07 | View | ||
| 2017-11-21 | Yoseph Bornstein | Disposed 45000 @ 1.21 | View | ||
| 2017-10-24 | Yoseph Bornstein | Disposed 50000 @ 1.14 | View | ||
| 2017-10-17 | Yoseph Bornstein | Disposed 50000 @ 1.16 | View |
Following insider trading sentiment in Microbot Medical can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Microbot Medical has a market cap of 183.34 M, ROE of -31.87%. See Correlation Analysis for portfolio-level analysis. This suggests a position in Microbot Medical inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.Microbot Medical's Workforce Through the Years
A workforce review of Microbot Medical matters because hiring and staffing trends often say something about growth plans, cost discipline, and management expectations. Current projections suggest a workforce around slightly above 130 employees by April 2026, which should be reviewed alongside revenue and margin trends.Macro event markers
Microbot Medical Management Team Effectiveness
The company has return on total asset (ROA) of -20.17 % implying that asset-level returns are negative, losing $20.17 per $100. This lags far behind comparable companies. Similarly, it shows a return on stockholder's equity (ROE) of -31.87 %, indicating that the business is consuming rather than creating equity value.As of this month (March), Common Stock Shares Outstanding is projected to grow to approximately 18.9 M, while Net Loss is projected to decrease toward slightly above -15.9 M.
Stock Ownership Analysis
About 18.0% of the company shares are owned by institutional investors. The book value of Microbot Medical was now reported as 1.19. The company has Price/Earnings To Growth (PEG) ratio of 0.7. Microbot Medical recorded a loss per share of 0.45. The company last dividend was issued on the 5th of September 2018. The firm completed a 1:15 stock split on 5th of September 2018.Reviewing share-based compensation in Microbot Medical helps investors understand how management balances employee incentives against dilution risk. Shares outstanding are near 67.2 M. That is why investors should compare compensation intensity with revenue growth, margin progress, and free-cash-flow generation.
Microbot Medical Quarterly Liabilities And Stockholders Equity | 81.76 Million |
Stock Institutional Investors
Institutional ownership matters in Microbot Medical because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Stifel Financial Corp | 2025-09-30 | 157.5 K | Omers Administration Corp | 2025-12-31 | 146 K | Bridgeway Capital Management, Llc | 2025-12-31 | 111 K | Millennium Management Llc | 2025-09-30 | 84.8 K | Northern Trust Corp | 2025-09-30 | 80.1 K | Two Sigma Investments Llc | 2025-12-31 | 61.1 K | Lpl Financial Corp | 2025-09-30 | 49.9 K | Cubist Systematic Strategies, Llc | 2025-09-30 | 39 K | Tower Research Capital Llc | 2025-09-30 | 36.1 K | Vanguard Group Inc | 2025-12-31 | 3.3 M | Atlantic Trust Group, Llc | 2025-12-31 | 1.5 M |
Insider Trading Activities
Insider trading disclosures for Microbot Medical offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 183.34 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
Outstanding Bonds
Reviewing Microbot Medical bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
About 82.48% of Microbot Medical outstanding shares are held by general public with 17.52% by institutional investors. Microbot Medical has approximately 18% of its outstanding shares held by institutional investors, with 82% in public hands. Shares in Circulation | First Issued 1991-03-31 | Previous Quarter 36.5 M | Current Value 48.1 M | Average Shares Outstanding 2.9 M | Quarterly Volatility 6.5 M |
Macro event markers
Microbot Stock Holders Distribution
Institutional ownership analysis for Microbot Medical matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Microbot Medical Market Cap and Value
Microbot Medical Workforce Comparison
Microbot Medical is rated below average in number of employees relative to competitors. The total workforce of Health Care industry is now estimated at about 3,899. Microbot Medical maintains roughly 20.0 in number of employees contributing less than 1% to equities under Health Care sector.
Microbot Medical Insider Trading History
Insider trading disclosures for Microbot Medical offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 183.34 Million. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2023-12-01 | 6.0 | 6 | 1 | 445,308 | 25,000 |
| 2020-12-01 | 0.8 | 4 | 5 | 11,084 | 64,881 |
| 2020-09-01 | 1.5 | 3 | 2 | 36,395 | 15,119 |
| 2019-12-01 | 5.0 | 5 | 1 | 19,760 | 40,000 |
| 2017-12-01 | 0.2917 | 7 | 24 | 1,325,007 | 576,795 |
| 2017-09-01 | 0.0741 | 2 | 27 | 1,812,712 | 450,610 |
| 2016-12-01 | 0.4 | 2 | 5 | 11,530,006 | 8,685,233 |
| 2016-06-01 | 0.5 | 1 | 2 | 48,077 | 7,918 |
| 2016-03-01 | 2.8333 | 17 | 6 | 4,240,010 | 146,370 |
| 2015-12-01 | 1.0 | 1 | 1 | 31,250 | 104,549 |
| 2015-06-01 | 0.5 | 1 | 2 | 12,255 | 35,476 |
| 2015-03-01 | 4.75 | 19 | 4 | 4,196,174 | 37,552 |
| 2014-09-01 | 1.0 | 1 | 1 | 150,000 | 0.00 |
| 2014-06-01 | 0.1667 | 1 | 6 | 9,329 | 173,400 |
| 2014-03-01 | 1.8 | 9 | 5 | 659,611 | 90,595 |
| 2013-09-01 | 3.0 | 3 | 1 | 18,299 | 877.00 |
| 2013-06-01 | 1.0 | 11 | 11 | 2,064,312 | 28,553 |
| 2013-03-01 | 0.6 | 3 | 5 | 30,414 | 102,982 |
| 2012-09-01 | 1.5 | 3 | 2 | 46,113 | 17,015 |
| 2012-06-01 | 0.625 | 5 | 8 | 53,708 | 30,380 |
| 2012-03-01 | 8.0 | 8 | 1 | 863,068 | 16,709 |
| 2011-09-01 | 2.0 | 2 | 1 | 24,585 | 856.00 |
| 2011-06-01 | 0.4 | 4 | 10 | 39,847 | 270,083 |
| 2011-03-01 | 0.4286 | 3 | 7 | 213,519 | 145,119 |
| 2010-09-01 | 0.5 | 1 | 2 | 10,000 | 208,559 |
| 2010-06-01 | 2.1429 | 15 | 7 | 3,590,000 | 82,703 |
| 2010-03-01 | 0.125 | 1 | 8 | 10,000 | 219,555 |
| 2009-12-01 | 2.0 | 2 | 1 | 20,000 | 3,647 |
| 2009-09-01 | 4.0 | 4 | 1 | 163,333 | 25,000 |
| 2009-06-01 | 0.8824 | 15 | 17 | 1,177,364 | 671,141 |
| 2009-03-01 | 0.2 | 1 | 5 | 10,000 | 131,220 |
| 2008-09-01 | 1.0 | 2 | 2 | 210,000 | 150,000 |
| 2008-06-01 | 0.0909 | 3 | 33 | 57,700 | 335,400 |
| 2008-03-01 | 2.5 | 5 | 2 | 917,500 | 40,000 |
| 2007-12-01 | 0.2 | 2 | 10 | 20,000 | 100,000 |
| 2007-09-01 | 5.0 | 5 | 1 | 846,000 | 450,000 |
| 2007-03-01 | 5.0 | 5 | 1 | 312,000 | 146,000 |
| 2006-12-01 | 3.5 | 7 | 2 | 215,742 | 97,000 |
| 2005-12-01 | 5.0 | 5 | 1 | 21,381 | 425,000 |
| 2005-06-01 | 3.5 | 7 | 2 | 84,942 | 133,720 |
| 2005-03-01 | 5.0 | 5 | 1 | 13,436 | 20,000 |
| 2004-03-01 | 0.2105 | 4 | 19 | 11,745 | 1,037,385 |
| 2003-12-01 | 0.6667 | 8 | 12 | 31,796 | 348,945 |
| 2003-09-01 | 1.0 | 2 | 2 | 4,659 | 0.00 |
Microbot Medical Notable Stakeholders
Stakeholders matter for Microbot Medical because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Harel Gadot | Chairman of the Board and Presidentident, CEO | Profile | |
| MSc MBA | CTO Israel | Profile | |
| Yoseph Bornstein | COFounder Director | Profile | |
| Michal Ahuvia | Director Operations | Profile | |
| Naama Moav | Vice Resources | Profile | |
| Rachel Vaknin | Chief Officer | Profile | |
| Eyal MD | Chief Board | Profile | |
| Paul Mullen | Vice Sales | Profile | |
| Pr DSc | Scientific CoFounder | Profile | |
| Juan DiazCartelle | Chief Officer | Profile | |
| Michael Lytle | Head Analytics | Profile | |
| Allison Rosefort | Vice Marketing | Profile | |
| Christina Bailey | Vice Sales | Profile |
Management Information & Data Sources
Microbot Medical is a micro-cap company in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care. Executive review focuses on insiders, senior management, and employee signals. Employee and executive trends can help explain changes in cost structure, growth capacity, or strategic execution. CEO is Harel Gadot with 20 employees and 13 reported executives.
This section for Microbot Medical is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Analyst inputs may be included when coverage is available. Values may update on different source schedules. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Michael Smolkin - Member of Macroaxis Board of DirectorsWorkforce Efficiency and Productivity
Investors reviewing Microbot Medical can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Microbot Medical Manpower Efficiency
Return on Microbot Medical Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 572.1K | |
| Net Loss Per Executive | 880.2K | |
| Working Capital Per Employee | 167.9K | |
| Working Capital Per Executive | 258.4K |
Additional Tools for Microbot Stock Analysis
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |